全文获取类型
收费全文 | 183篇 |
免费 | 3篇 |
专业分类
儿科学 | 8篇 |
妇产科学 | 1篇 |
基础医学 | 16篇 |
口腔科学 | 5篇 |
临床医学 | 43篇 |
内科学 | 37篇 |
皮肤病学 | 4篇 |
神经病学 | 6篇 |
外科学 | 31篇 |
综合类 | 1篇 |
预防医学 | 7篇 |
眼科学 | 1篇 |
药学 | 25篇 |
肿瘤学 | 1篇 |
出版年
2015年 | 2篇 |
2014年 | 5篇 |
2013年 | 2篇 |
2012年 | 2篇 |
2011年 | 3篇 |
2010年 | 5篇 |
2009年 | 4篇 |
2008年 | 3篇 |
2007年 | 3篇 |
2006年 | 2篇 |
2005年 | 4篇 |
2003年 | 3篇 |
2001年 | 5篇 |
1999年 | 8篇 |
1998年 | 6篇 |
1997年 | 7篇 |
1996年 | 9篇 |
1995年 | 4篇 |
1994年 | 6篇 |
1993年 | 6篇 |
1992年 | 4篇 |
1991年 | 1篇 |
1990年 | 4篇 |
1989年 | 8篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1985年 | 1篇 |
1984年 | 4篇 |
1983年 | 4篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1980年 | 6篇 |
1979年 | 4篇 |
1978年 | 4篇 |
1977年 | 1篇 |
1976年 | 3篇 |
1975年 | 2篇 |
1974年 | 2篇 |
1973年 | 2篇 |
1972年 | 2篇 |
1965年 | 2篇 |
1959年 | 5篇 |
1958年 | 4篇 |
1957年 | 3篇 |
1956年 | 10篇 |
1955年 | 3篇 |
1954年 | 4篇 |
1953年 | 1篇 |
1951年 | 1篇 |
1948年 | 1篇 |
排序方式: 共有186条查询结果,搜索用时 15 毫秒
41.
42.
Hamster renal cortical slices bioactivated the synthetic estrogen,diethylstilbestrol (DES), to reactive metabolites that boundirreversibly to cellular proteins. Incubation of the slicesfor 30 mm at 37°C with 5 mM diethyl maleate prior to theaddition of 50 nM [3H]DES for 60 min increased the nonextractablebinding of [3H]DES metabolites to cellular protein by 150%,whereas addition of 5 mM glutathione (GSH) decreased the irreversiblebinding of [3H]DES by 17%. The addition of the 5 mM GSH to theincubation medium caused a 24% increase in tissue nonproteinsulfhydryl (NP-SH) content as estimated by reaction with Eliman'sreagent after 30 min at 37°C, while the addition of diethylmaleate for the same time period depleted tissue NP-SH levelsby 54%. Kidneys from hamsters treated with the GSH synthesisinhibitor L-buthionine-(S, R)-sulfoximine at a dosage of 1 mmol/kgbody wt for 2 hr had 45% of the NP-SH content as compared withkidneys of saline-treated controls. The irreversible bindingof [3H]DES metabolites was increased by 60% in renal corticalslices from L-buthionine sulfoximine-treated hamsters. Non-extractablebinding of [3H]DES metabolites to renal DNA was not observed.These results sug gest that GSH, the predominate NP-SH in thecell, protects against the irreversible binding of DES metabolitesto cellular macromolecules. 相似文献
43.
44.
45.
MARIANGELA SANTIAGO MD ROBERTO PÉREZ-RANGEL MD ANGELO D''UGO MD GIAMPIERO GRISELLI MD GARIGIN IGITIAN MD ILDEFONSO GARCIA MARTIN MD GEIR B. NESHEIM MD USAMA SAAD EDDIN MD GEOFF SMITH SA GERARD W. BRADY MBBS CHERINE CHAKER MD 《Dermatologic surgery》2007,33(1):35-44
BACKGROUND: There is presently no treatment for scalp scars that is fully satisfactory. The modalities of treatment currently in use are surgery, hair transplantation, and micropigmentation. Scalp implantation with artificial hair fibers is used by some physicians as an adjunctive treatment. OBJECTIVE: The objective was to assess the utility of artificial hair fibers to treat scalp scars. METHODS: Data were collected by the principal author from 10 hair restoration practitioners who tested polyamide hair fiber (Biofibre CE 0373/TGA by Medicap Ltd., Carpi (MO), Italy) implantation for scalp scars. RESULTS: Artificial hair fiber implantation occurred between June 1996 and December 2000, and observations continued until December 2004. Data from 54 scars from 44 patients treated showed: (1) no complications in 49 scars (90.7%); (2) mild adverse outcomes in 4 scars (7.4%)-temporary superficial inflammation-infection that subsided following topical cortisone and local/systemic antibiotic treatment; and (3) moderately adverse outcomes in 1 scar (1.9%)-significant inflammation and generalized infection requiring removal of artificial implant to alleviate. Occasional minor skin reactions, sebum plugs, and hyperseborrhea were successfully controlled and well accepted by patients. Fiber fall rate was 20% on average per annum. CONCLUSION: Data show that polyamide hair fiber restoration can be considered an adjunctive treatment for scalp scars in selected cases. 相似文献
46.
47.
GIUSEPPE BORIANI MAURO BIFFI ALESSANDRO CAPUCCI GIAN LUCA BOTTO TIZIANA BROFFONI IDA RUBINO STEFANO DELLA CASA MARIO SANGUINETTI ANGELO BRANZI BRUNO MAGNANI 《Pacing and clinical electrophysiology : PACE》1998,21(11):2465-2469
The efficacy and safety of propafenone as an oral loading dose (600-mg single oral dose) in converting recent-onset atrial fibrillation (≤ 7 days duration) to sinus rhythm were evaluated in a single-blind, placebo-controlled study according to patients' age. Overall, 240 hospitalized patients, NYHA Class ≤ 2 without signs or symptoms of heart failure were enrolled: among patients aged ≤ 60 years, 55 were allocated to propafenone treatment and 59 to placebo, respectively, and among patients aged > 60 years, 64 were allocated to propafenone treatment and 62 to placebo, respectively. Results: In each age group, the likelihood of conversion to sinus rhythm was significantly greater after propafenone compared with plocebo at 3 and 8 hours. For patients aged ≤ 60 years, corresponding odd ratios were 3.78 (95% CI = 1.80–7.92, P = 0.04) at 3 hours and 4.74 (95% CI = 2.12–10.54, P = 0.02) at 8 hours; for patients aged > 60 years odd ratios were 5.03 (95% CI = 2.08–12.12, P = 0.02) at 3 hours and 6.75 (95% CI = 3.28–73.86, P = 0.01) at 8 hours, respectively. Logistic regression analysis showed that conversion to sinus rhythm within 3 hours was predicted by age ≤ 60 years (P = 0.0064) and by propafenone treatment (P < 0.0001), and conversion to sinus rhythm within 8 hours was predicted by age ≤ 60 years (P = 0.0467) and by propafenone treatment (P < 0.0001). The occurrence of adverse effects was observed in 14%-16% of propafenone treated patients and in 8% of placebo treated patients without significant differences according to age. In conclusion, in patients with recent-onset atrial fibrillation without signs of heart failure, propafenone as a single oral loading dose is effective. It is also effective in selected elderly subjects with a favorable safety profile. Moreover, spontaneous conversion to sinus rhythm appears to occur less frequently in elderly patients. 相似文献
48.
ANGELO AURICCHIO LUIGI SOMMARIVA RODNEY W. SALO ANTONIO SCAFURI LUIGI GHIARIELLO 《Pacing and clinical electrophysiology : PACE》1993,16(10):2034-2043
Medical therapy often fails to control symptoms of severe heart failure. The possibility of modifying to some degree the global ventricular performance with the implantation of a physiological dual chamber pacemaker, set with a short atrioventricular delay (100 msec), has been adopted in two patients with severe heart failure due to coronary artery disease. The baseline clinical condition of both patients was characterized by leg edema, ascites, dyspnea at rest, or even orthopnea with a functional New York Heart Association (NYHA) class III-IV. Acute measurements of hemodynamic and echocardiographic parameters during stepwise shortening of AV interval guided the pacemaker implantation and setting of AV delay in the chronic phase. Within a few days after pacemaker implantation, both patients considerably improved their clinical status as well as their functional NYHA class, improving to class U in one patient and to class II-III in the other patient. In addition, modification of systolic and diastoJic parameters paralleled these improvements functional class and clinical condition. Pacemaker therapy in severe heart failure refractory to medical therapy can be of considerable benefit in patients whose quality-of-life is severely compromised when pharmacological therapy is no longer effective. Acute hemodynamic and echocardiographic testing is useful in assessing the most appropriate AV delay and pacing mode. 相似文献
49.
50.
K. K. SNOW H. L. BONKOVSKY R. J. FONTANA H.‐Y. KIM R. K. STERLING A. M. DI BISCEGLIE T. R. MORGAN J. L. DIENSTAG M. G. GHANY The HALT‐C Trial Group 《Alimentary pharmacology & therapeutics》2010,31(7):719-734
Aliment Pharmacol Ther 31 , 719–734